Ohio State physicians, faculty sign ‘no confidence’ letter about hospital CEO

Some 25 physicians and professors in the Ohio State University College of Medicine signed a letter criticizing Sheldon Retchin, MD, CEO of the OSU Wexner Medical Center, and his top executives.

According to the Columbus Dispatch, the “no confidence” letter alleged Retchin has disrespected the hospital’s mission, setting “unrealistic clinical effort and research funding expectations that are incompatible with academic medicine.” The result has been reduced morale among the staff and divisions between the medical center and other OSU institutions, like its cancer center.

In addition, the letter complained about the college of medicine’s dean, Craig Kent, MD, adopting Retchin’s leadership style, creating a “confusing and continually changing faculty hiring process” which had led to a shortage of physicians and encouraged some to resign or take early retirements.

The letter seemed to attract the attention its signatories wanted, as OSU’s president and provost met with the physicians on May 3.

Read the full article at the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.